Acurx Pharmaceuticals (NASDAQ:ACXP) Given “Buy” Rating at HC Wainwright

Acurx Pharmaceuticals (NASDAQ:ACXP)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $31.00 price target on the stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Stock Performance

Shares of NASDAQ ACXP traded down $0.06 during trading on Tuesday, reaching $1.28. The company had a trading volume of 91,237 shares, compared to its average volume of 1,111,844. Acurx Pharmaceuticals has a 52 week low of $1.28 and a 52 week high of $8.34. The stock has a market cap of $7.12 million, a PE ratio of -0.48 and a beta of -2.02. The business’s 50 day moving average price is $1.43 and its 200-day moving average price is $2.08.

Acurx Pharmaceuticals (NASDAQ:ACXP) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.15). Equities analysts anticipate that Acurx Pharmaceuticals will post -2 earnings per share for the current year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.